Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus (Q38024321)

27 August 2017

title

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus (English)

1 reference

27 August 2017

0 references

Claire M Issa

1

1 reference

27 August 2017

Sami T Azar

series ordinal

2

1 reference

27 August 2017

language of work or name

1 reference

1 October 2012

1 reference

27 August 2017

published in

Current diabetes report

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

560-567

1 reference

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Exon duplication and divergence in the human preproglucagon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucose, Insulin, Pancreatic Glucagon and Glucagon-like Immunoreactive Materials in the Plasma of Normal and Diabetic Children. Effect of the Initial Insulin Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Type 1 diabetes: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-like peptide 1(GLP-1) in biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-like peptide-1 binding to rat hepatic membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

The NOD mouse: a model of immune dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Exendin-4 modulates diabetes onset in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 Club Meeting, Marseille, 28-29 May 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Beta cell mass in diabetes: a realistic therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-012-0291-6

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells

21 January 2018

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

12 December 2020

Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats

1 reference

12 December 2020

Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes

1 reference

12 December 2020

A Gastric Inhibitory Polypeptide. I. The Amino Acid Composition and the Tryptic Peptides

1 reference

12 December 2020

Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment

1 reference

12 December 2020

The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects

1 reference

12 December 2020

Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis

1 reference

12 December 2020

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

1 reference

12 December 2020

Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes

1 reference

12 December 2020

Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors

1 reference

12 December 2020

Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

1 reference

12 December 2020

Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes

1 reference

12 December 2020

Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes

1 reference

12 December 2020

Further purification of a polypeptide demonstrating enterogastrone activity

1 reference

12 December 2020

Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle

1 reference

12 December 2020

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

1 reference

12 December 2020

Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans

1 reference

12 December 2020

Chromatographic pattern of extrapancreatic glucagon and glucagon-like immunoreactivity before and during stimulation by epinephrine and participation of glucagon in epinephrine-induced hepatic glucose overproduction

1 reference

12 December 2020

Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue

1 reference

12 December 2020

The mechanism of pancreatic secretion

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM

1 reference

12 December 2020

Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence

1 reference

12 December 2020

10.1007/S11892-012-0291-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1026090957

0 references

1 reference